Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism
Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism
- Results from Phase 3 long-term extension study of relacorilant to treat patients with hypercortisolism were presented at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
- 116 patients with hypercortisolism were enrolled with treatment duration of up to six years
- Results provide further evidence of relacorilant's potential benefit as a treatment for patients with hypercortisolism
- 在世界胰島素抵抗、糖尿病與心血管疾病大會(WCIRDC)上，公佈了用於治療高皮質醇血癥患者的relacorilant III期長期擴展研究的結果。
- 116名高皮質醇血癥患者參與了研究，治療持續時間最長可達六年。
- 研究結果進一步證明了relacorilant作爲高皮質醇血癥患者治療的潛在好處。
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogenous hypercortisolism (Cushing's syndrome) at the WCIRDC. The results from this study demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements and relacorilant was well-tolerated, with a treatment duration of up to six years.
Corcept醫療公司（納斯達克：CORT）是一家商業階段公司，致力於通過調節皮質醇激素的影響，發現和開發治療嚴重內分泌、腫瘤、代謝和神經疾病的藥物。該公司在WCIRDC上公佈了其relacorilant用於治療內源性高皮質醇血癥（庫欣綜合徵）III期長期開放標籤擴展研究的結果。該研究的結果表明，接受relacorilant治療的患者在心臟代謝方面經歷了臨床意義重大的持久改善，並且relacorilant耐受良好，治療持續時間最長可達六年。
譯文內容由第三人軟體翻譯。
